The 29th March 2018 marked the one-year countdown to Brexit. While many companies in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity and bureaucracy of the regulatory landscape will increase dramatically if a ‘hard’ Brexit is implemented. As such, pharmaceutical manufacturers should be preparing for all eventualities.

Brexit: the implications on the pharma industry need to be discussed as a matter of priority.

As a CDMO with a presence in both the UK and mainland Europe, we are well positioned to support our customers through this transition and have a taskforce dedicated to meeting the Brexit challenge head-on. We also expect to see a greater demand for outsourced manufacturing services from UK MAHs wishing to supply to Europe.

As we move closer to the deadline, Recipharm’s Senior Vice President, Quality Management, Thomas Beck spoke to inPharmaTechnologist regarding the need for more clarity from the EMA.

Read the full article here:

12-month countdown: Industry raises ‘hard’ Brexit concerns